X
API Suppliers
US DMFs Filed
CEP/COS Certifications
0
JDMFs Filed
Other Certificates
0
Other Suppliers
0
0
USA (Orange Book)
Europe
0
Canada
0
Australia
0
South Africa
0
Uploaded Dossiers
0
U.S. Medicaid
0
Annual Reports
0
0
https://www.globenewswire.com//news-release/2023/12/18/2797670/29236/en/Cara-Therapeutics-Announces-Outcome-from-Dose-Finding-Part-A-of-KIND-1-Study-Evaluating-Oral-Difelikefalin-for-Moderate-to-Severe-Pruritus-in-Patients-with-Atopic-Dermatitis.html
https://www.prnewswire.com/news-releases/kapruvia-difelikefalin-recommended-by-englands-nice-for-the-treatment-of-adults-with-moderate-to-severe-ckd-associated-pruritus-301827524.html
https://www.globenewswire.com/news-release/2023/05/18/2671614/29236/en/Kapruvia-difelikefalin-recommended-by-England-s-NICE-for-the-treatment-of-adults-with-moderate-to-severe-CKD-associated-pruritus.html
https://www.globenewswire.com/news-release/2022/09/28/2524125/29236/en/Cara-Therapeutics-Announces-Difelikefalin-KORSUVA-Injection-New-Drug-Application-Has-Been-Submitted-in-Japan.html
https://www.globenewswire.com/news-release/2022/09/08/2512494/29236/en/Cara-Therapeutics-Presents-Late-Breaking-Results-of-the-KOMFORT-Phase-2-Trial-of-Oral-Difelikefalin-for-Pruritus-in-Notalgia-Paresthetica-at-the-31st-EADV-Congress.html
https://www.globenewswire.com/news-release/2022/08/19/2501317/29236/en/Kapruvia-approved-in-Switzerland-with-additional-regulatory-decisions-expected-in-H2-2022.html
https://www.globenewswire.com/news-release/2022/06/30/2472003/29236/en/Cara-Therapeutics-Announces-Positive-Topline-Results-from-KOMFORT-Phase-2-Trial-of-Oral-Difelikefalin-for-the-Treatment-of-Pruritus-in-Patients-with-Notalgia-Paresthetica.html
https://www.ema.europa.eu/en/documents/overview/kapruvia-epar-medicine-overview_en.pdf
https://www.globenewswire.com/news-release/2022/04/04/2416080/29236/en/Cara-Therapeutics-Announces-Biomarker-Data-from-KALM-1-and-KALM-2-Trials-of-KORSUVA-difelikefalin-Injection-Selected-for-Presentation-at-National-Kidney-Foundation-Spring-Clinical-.html
https://ir.caratherapeutics.com/news-releases/news-release-details/cara-therapeutics-announces-oral-korsuvatm-difelikefalin
https://www.globenewswire.com/news-release/2022/02/18/2387857/29236/en/Cara-Therapeutics-to-Host-Virtual-R-D-Day-on-March-11-2022.html
https://www.globenewswire.com/news-release/2021/12/20/2355086/29236/en/Cara-Therapeutics-Announces-CMS-Grants-TDAPA-to-KORSUVA-difelikefalin-Injection.html
https://www.prnewswire.com/news-releases/swk-holdings-subsidiary-enteris-biopharma-receives-5-million-milestone-payment-from-cara-therapeutics-301441841.html
https://www.fiercepharma.com/pharma/after-failures-cara-and-vifor-s-korsuva-wins-fda-approval-for-treatment-pruritis-chronic
https://www.prnewswire.com/news-releases/enteris-biopharmas-licensing-partner-cara-therapeutics-announces-top-line-data-from-phase-2-trial-of-peptelligence-engineered-oral-korsuva-for-the-treatment-of-pruritus-in-patients-with-advanced-chronic-kidney-disease-ckd-300970448.html
https://www.in-pharmatechnologist.com/Article/2019/08/29/Enteris-licenses-oral-delivery-platform-to-Cara-Therapeutics
https://www.contractpharma.com/contents/view_breaking-news/2019-08-26/enteris-cara-therapeutics-enter-peptelligence-pact/
https://www.prnewswire.com:443/news-releases/enteris-biopharmas-feasibility-to-licensing-partner-cara-therapeutics-initiates-phase-2-trial-of-peptelligence-engineered-oral-korsuva-for-pruritus-in-patients-with-atopic-dermatitis-300882969.html
https://www.prnewswire.com/news-releases/enteris-biopharmas-feasibility-to-licensing-partner-cara-therapeutics-doses-first-patient-in-phase-2-trial-of-peptelligence-engineered-oral-korsuva-300683495.html
Market Place
Share 
